Fred G. J. Tijl

Publications by Year

Research Areas

Ocular Oncology and Treatments, Multiple Myeloma Research and Treatments, Hepatocellular Carcinoma Treatment and Prognosis, Immunotherapy and Immune Responses, Nanoplatforms for cancer theranostics

Most-Cited Works

• → Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver(2004)75 cited
• → Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver(2003)67 cited
• → Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients(2008)46 cited
• → Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases(2008)45 cited
• → Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial(2019)37 cited
• → Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study(2020)34 cited
• → Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial(2023)31 cited
• → Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: A clinical and pharmacologic evaluation(2007)28 cited
• → Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan(2017)27 cited
• → Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial(2022)22 cited